Trial Profile
Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Aug 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Docetaxel (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Nanology
- 06 Jun 2023 Results of 7 studies (NCT00666991, NCT03636256, NCT03077659, NCT04221828, NCT03029585, NCT03077685, NCT04314895) assessing safety findings in subjects co-administered LSAM-PTX or LSAM-DTX and common SOC therapies for treatment of carcinomas, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 01 Aug 2022 Results presented in a NanOlogy Media Release.
- 16 May 2022 Results published in the Journal of Urology